Since foretinib appears as a more potent inhibitor than crizotinib also in patients with ROS1-rearranged non-small-cell lung carcinoma [36], further in vivo studies revealed anti-tumorigenic effects of foretinib in lung metastasis [37] and in patients with sonic hedgehog-driven medulloblastoma [38]. The gene discussed is ROS1; the disease is non-small cell lung carcinoma.